申请人:DONG A PHARM CO LTD
公开号:WO2011122815A2
公开(公告)日:2011-10-06
This invention relates to a novel compound represented by the following Chemical Formula 1, a process for preparing it, and its pharmaceutically approved salt comprising it as an active ingredient. The compound of this invention is GLP 1 receptor regulating low molecular weight compound useful for treatment of metabolic diseases such as diabetes and obesity by regulating the function of glucagon like peptide 1 receptor (GLP 1 receptor) for the disease or disorder carried by GLP 1 since it has the effects on a drop of blood sugar and an improvement of insulin resistance.